News
Stay updated on Vesigen innovations
Sign up to receive the latest company news
Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139
Vesigen Therapeutics Presents Data on Recent Advances to its Engineered ARMMs Therapeutic Delivery Platform at ISEV 2021
CAMBRIDGE, Mass., May 18, 2021 /PRNewswire/ — Vesigen Therapeutics, Inc., a biotechnology company pioneering development of a novel extracellular vesicle-mediated ...
Vesigen Therapeutics Appoints Industry Veteran Dieter Weinand to Board of Directors
CAMBRIDGE, Mass., Apr. 6, 2021 /PRNewswire/ — Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology, ...
Vesigen Therapeutics Announces Issuance of U.S. Patent for Broad Applications of ARMMs Technology
CAMBRIDGE, Mass., Mar. 16, 2021 /PRNewswire/ — Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology ...
Vesigen Therapeutics Names Lucio Iannone to Board of Directors
CAMBRIDGE, Mass., Dec. 1, 2020 /PRNewswire/ — Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology ...
Vesigen Therapeutics launches with USD 28.5 million Series A investment led by Leaps by Bayer and Morningside Ventures
Investment addresses today’s challenge to efficiently transport next-generation therapeutics such as cell and gene therapy to the target and unlock ...
ARMMs as a versatile platform for intracellular delivery of macromolecules
Wang, Q., Yu, J., Kadungure, T. et al., Nat Commun 9, 960 (2018) ...
Stay Connected
